NGENLA

(Ngenla)

PreclinicalSmall molecule

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

NGENLA is one of 34 small molecule programs targeting Growth. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

GrowthActive, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Preclinical

35 2

Lovenox

Sanofi

Preclinical

2 3

Aricept

Eisai

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Lenvima

Eisai

Preclinical

1 6

Herceptin

OOrganon and Co

Preclinical

4 7

Somavaratan

Glucophage

2 9

EGRIFTA WR

TTheratechnologies

Preclinical

2 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Active, not recruiting

Growth

NCT05509894

Q2 2029

Active, not recruiting

Study completion

NCT05602766

Clinical

Trials by Indication[1]

Growth1 trial

Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone

Active, not recruiting· Pfizer logo

Pfizer··NCT05509894·565 enrolled

Unspecified1 trial

Ngenla Subcutaneous Injection Special Investigation

Active, not recruiting· Pfizer logo

Pfizer··NCT05602766·1 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 27, 2023

NGENLA

BLA BLA761184

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ngenla. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ngenla compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ngenla. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761184). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

NGENLA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2029

Trials by Indication[1]

Growth1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News